Stock Scorecard

Stock Summary for Kronos Bio Inc (KRON) - $0.88 as of 11/13/2025 2:46:16 AM EST

Total Score

12 out of 30

Safety Score

10 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for KRON

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for KRON

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for KRON

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for KRON

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for KRON (10 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for KRON

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders - American Axle & Mfg Hldgs ( NYSE:AXL ) , Kronos Bio ( NASDAQ:KRON ) 5/18/2025 10:41:00 PM
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - PRA, KRON, AXL, SWTX 5/17/2025 5:00:00 PM
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - Kronos Bio ( NASDAQ:KRON ) , Regulus Therapeutics ( NASDAQ:RGLS ) 5/15/2025 10:52:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. ( Nasdaq - KRON ) , Regulus Therapeutics Inc. ( Nasdaq - RGLS ) , Longevity Health Holdings, Inc. ( Nasdaq - XAGE ) , Southern States Bancshares, Inc. ( Nasdaq - SSBK ) 5/15/2025 8:17:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. ( Nasdaq - KRON ) , Regulus Therapeutics Inc. ( Nasdaq - RGLS ) , Coeptis Therapeutics Holdings, Inc. ( Nasdaq - COEP ) , Pacific Premier Bancorp, Inc. ( Nasdaq - PPBI ) 5/1/2025 3:27:00 PM
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - Kronos Bio ( NASDAQ:KRON ) 5/1/2025 12:30:00 PM
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul - Kronos Bio ( NASDAQ:KRON ) 11/27/2024 1:59:00 PM
Kronos Bio Announces CEO Transition and Reduction in Force - Kronos Bio ( NASDAQ:KRON ) 11/27/2024 12:30:00 PM
Kronos Bio Announces CEO Transition and Reduction in Force 11/27/2024 12:30:00 PM
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul - A.O. Smith ( NYSE:AOS ) , Anglo American ( OTC:AAUKF ) 11/17/2024 7:49:00 AM

Financial Details for KRON

Company Overview
Ticker KRON
Company Name Kronos Bio Inc
Country N/A
Description Kronos Bio, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery and development of new cancer therapies. The company is headquartered in San Mateo, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 0.88
Price 4 Years Ago 13.59
Last Day Price Updated 11/13/2025 2:46:16 AM EST
Last Day Volume 54,089
Average Daily Volume 1,206,555
52-Week High 1.40
52-Week Low 0.65
Last Price to 52 Week Low 35.38%

Valuation Measures
Trailing PE N/A
Industry PE N/A
Sector PE N/A
5-Year Average PE -2.69
Free Cash Flow Ratio 0.59
Industry Free Cash Flow Ratio N/A
Sector Free Cash Flow Ratio N/A
Current Ratio Most Recent Quarter 12.93
Total Cash Per Share 1.50
Book Value Per Share Most Recent Quarter 1.31
Price to Book Ratio 0.67
Industry Price to Book Ratio N/A
Sector Price to Book Ratio N/A
Price to Sales Ratio Twelve Trailing Months 5.84
Industry Price to Sales Ratio Twelve Trailing Months N/A
Sector Price to Sales Ratio Twelve Trailing Months N/A
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 60,969,000
Market Capitalization 53,652,720
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 23.60%
Reported EPS 12 Trailing Months -1.07
Reported EPS Past Year -0.14
Reported EPS Prior Year -1.22
Net Income Twelve Trailing Months -64,485,000
Net Income Past Year -86,079,000
Net Income Prior Year -112,673,000
Quarterly Revenue Growth YOY -26.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -342.00%

Balance Sheet
Total Cash Most Recent Quarter 91,577,000
Total Cash Past Year 84,571,000
Total Cash Prior Year 64,326,000
Net Cash Position Most Recent Quarter 91,577,000
Net Cash Position Past Year 84,571,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 87,580,000
Total Stockholder Equity Prior Year 159,078,000
Total Stockholder Equity Most Recent Quarter 79,812,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -54,393,000
Free Cash Flow Per Share Twelve Trailing Months -0.89
Free Cash Flow Past Year -65,439,000
Free Cash Flow Prior Year -79,261,000

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.04
MACD Signal 0.03
20-Day Bollinger Lower Band 0.63
20-Day Bollinger Middle Band 0.85
20-Day Bollinger Upper Band 1.07
Beta 1.64
RSI 68.03
50-Day SMA 1.51
150-Day SMA 0.00
200-Day SMA 3.82

System
Modified 11/13/2025 2:46:17 AM EST